secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0001193125-24-157554
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO J. Scott Wolchko assumes CFO role after Edward Dulac's resignation; stock plan expanded
--------------------------------------------------------------------------------

- CFO Edward Dulac resigned effective June 14, 2024; CEO J. Scott Wolchko appointed as CFO and principal financial/accounting officer.
- Wolchko previously served as CFO from company inception until August 2020; no change to his compensation.
- Stockholders approved amendment to 2022 Stock Option Plan, increasing available shares by 8,000,000 to 17,500,000 total.
- Other proposals passed: election of three Class II directors, ratification of EY, say-on-pay, officer exculpation amendment.
- Broker non-votes were ~6.7M on most items; say-on-pay passed with ~65.4M for vs 25.6M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312524157554/0001193125-24-157554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312524157554/d839723d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-157554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer